Balyasny Asset Management
CTMX icon

Balyasny Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Balyasny Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-900,000
Closed -$3.83M – 2986
2025
Q4 		$3.83M Hold
900,000
– – ﹤0.01% 1531
2025
Q3 		$2.87M Buy
+900,000
New +$2.03M ﹤0.01% 1633

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Balyasny Asset Management's CTMX Position: Q2 2026 in Review

Balyasny Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 730,844 shares — an estimated $3.43M sold.

Balyasny Asset Management first reported a position in CTMX in Q1 2018 and held it in 11 quarters. The position peaked at $16.5M in Q4 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Balyasny Asset Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 730,844 CytomX Therapeutics shares in Q2 2026, an estimated $3.43M.
  • Balyasny Asset Management first reported a position in CytomX Therapeutics in Q1 2018 and held it in 11 quarters.
  • Balyasny Asset Management's CytomX Therapeutics position peaked at $16.5M in Q4 2025.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.